Abstract
6013 Background: Lenvatinib (LEN), an oral multikinase inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT, significantly prolonged progression-free survival (PFS) vs placebo in the phase 3 SELECT...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have